PRINCETON, NJ and REHOVOT, ISRAEL - October 17, 2013 - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company's Cancer Origin Test™ will be highlighted in a poster presentation at the upcoming American Society of Human Genetics Annual Meeting 2013 (ASHG 2013) taking place October 22-26 at the Boston Convention and Exhibition Center in Boston, Mass.
Poster presenters will be available October 23rd from 10:30 a.m. to 12:00 p.m., and posters will be available for viewing beginning October 23rd at 10:30 a.m. until October 25th at 2:00 p.m. The following poster highlighting Rosetta Genomics' Cancer Origin Test will be presented at ASHG 2013:
- "Value of microRNA-based molecular profiling in Cancer of Unknown Primary (CUP) cases for familial cancer risk assessment and genetic counseling," will be presented by study author and medical geneticist, E. Robert Wassman, MD, FAAP, FACMG, and Rosetta Genomics' Chief Medical Officer. Poster Number 3501W
Prediction of the risk of cancer in families, genetic testing, counseling and other options are heavily dependent upon accurate diagnosis of cancers that have occurred in other family members. When a deceased relative's medical records are incomplete or inaccurate in any way, appropriate counseling and decision-making is impaired. Relatives of patients who die from cancers of unknown or uncertain primary (CUP), which occurs in over 3-5% of all cancers, are particularly challenged in accurately assessing their cancer risk.
Molecular profiling with Rosetta's microRNA-based Cancer Origin Test has been shown to effectively identify the underlying tumor type in CUP cases, and allows for more accurate identification of potentially unrecognized genetic risks, or the correct assessment when risk might otherwise have been over-estimated by the family or their genetic counselors. As microRNA has been shown to be particularly stable in FFPE preserved tumor blocks for over 10-years, archival material analysis of a deceased relative's cancer when CUP or uncertain results confounded a pedigree is now possible with this assay.
The poster presentation highlights a study outlining the findings in a population of deceased CUP patients. The study demonstrated the frequency with which the results might impact the cancer risk assessment in their family if this test were not utilized to resolve the uncertainty of the actual cancer diagnosis of the deceased CUP patient. The study concluded that, "microRNA profiling in CUP patients has an incrementally important clinical utility in uncovering previously unknown or inaccurate genetic risks associated with specific cancer diagnoses in at least one-third of cases, potentially directing specific genetic testing for relatives."
"The Cancer Origin Test may be of importance in clarifying the disease pedigree for families with a history of CUP seeking information on their genetic risk of cancer. Our findings showed a high frequency of breast, ovarian and colon cancers, including significant numbers of male breast cancers in the CUP population, which clearly indicates that pedigrees with unresolved diagnoses from CUP cases could be highly informative if the Cancer Origin Test is applied," said Dr. Wassman. "In addition, our identification of exceedingly rare cancers with high genetic risks in families further highlights the value of this testing."
About the American Society of Human Genetics Annual Meeting
The ASHG Annual Meeting is the largest human genetics meeting and exposition in the world. ASHG 213 is expected to attract over 6,500 scientific attendees, plus nearly 200 exhibiting companies. ASHG members and leading scientists from around the world are selected to present their research findings at invited, platform, and poster sessions. Abstracts of work submitted for presentation at the Annual Meeting are published online. ASHG's Annual Meeting also features a trade show floor that offers attendees the opportunity to view state-of-the-art medical and laboratory equipment, products, services, and computer software designed to enhance human genetics research, teaching, and consultation.
About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and the benign oncocytoma. Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Cancer Origin Test, 60,000 from the Mesothelioma Test, 65,000 from the Kidney Cancer Test and 226,000 patients from the Lung Cancer Test. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.
About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test, the Cancer Origin Test improving the ability of physicians to accurately diagnose CUP, the Cancer Origin Test's ability to help physicians to optimize treatment, Rosetta's development or commercialization of molecular diagnostics, the market acceptance of Rosetta's cancer testing services, particularly the Cancer Origin Test, the clinical utility of microRNA profiling in CUP patients in uncovering previously unknown or inaccurate genetic risks associated with specific cancer, the possible importance of the Cancer Origin Test™ in clarifying the pedigree in families seeking information on their genetic risk of cancer and the value of such testing constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
President & CEO
(609) 419-9000, ext. 1326
Anne Marie Fields
SOURCE: Rosetta Genomics, Ltd.